TY - JOUR
T1 - Personalized combined modality therapy for locally advanced non-small cell lung cancer
AU - Nathan Kim, D.
AU - Nam, Taek Keun
AU - Choe, Kevin S.
AU - Choy, Hak
PY - 2012/6
Y1 - 2012/6
N2 - Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.
AB - Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.
KW - Combined modality therapy
KW - Epidermal growth factor receptor
KW - Individualized medicine
KW - Lung neoplasms
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84866904966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866904966&partnerID=8YFLogxK
U2 - 10.4143/crt.2012.44.2.74
DO - 10.4143/crt.2012.44.2.74
M3 - Review article
C2 - 22802745
AN - SCOPUS:84866904966
SN - 1598-2998
VL - 44
SP - 74
EP - 84
JO - Cancer Research and Treatment
JF - Cancer Research and Treatment
IS - 2
ER -